Euglycemic Diabetic Ketoacidosis in a Diabetic Patient Treated with SGLT2 Inhibitor

Abstract

Euglycemic DKA (EuDKA) has been described in diabetic patients with poor oral intake, low carbohydrate/low calorie intake, decreased/missed insulin dose, infections, drug (cocaine) overdose, excessive alcohol consumption, surgical/ traumatic stress [2-9] and recent ly with COVID 19 infection [10,11] (Figure 1). The incidence of EuDKA has increased with introduction of the sodium glucose transporter 2 inhibitors (SGLT2i): Canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflosin, tofogliflozin, sotogliflozin [6,[7][8][9][10][11][12]. SGLT2 inhibitors are a new class of antihyperglycemic drugs which have gained widespread use